Epigenetics specialist CellCentric Ltd reached an agreement with Takeda, Japan’s largest pharmaceutical company, for the further development of an epigenetic target owned by the Cambridge University spin-out. The company says that its research to date suggests the protein plays an important role in cancer development, and inhibitors to the target could offer new ways to treat the disease. After fully validating the undisclosed target, Takeda will also have an option to license the product.
The target is one of fourteen that CellCentric has identified through its worldwide network of 23 academic research laboratories.
Will West, Chief Executive of CellCentric, said epigenetics is increasingly seen as a key area for target discovery. “We are delighted to build our relationship with Takeda, which is showing real commitment to the area.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
